MeTA Process and Progress in Jordan
-
Upload
metapresents -
Category
Health & Medicine
-
view
1.221 -
download
3
description
Transcript of MeTA Process and Progress in Jordan
Rania Bader
MeTA Consultant
MeTA Process and Progress in Jordan
MeTA 10/04/23 1
Jordan’s Fact Sheet
• Population: 5.8 million
• Health expenditure: 10.4 % of GDP (30% of this spent on medicines)
• Total Medicine Expenditure $ 338 Million
• Public Medicine Expenditure $ 112.6 Million
• 25% Medicine expenditure (public sector) 75 % Medicine expenditure (private sector)
• Local medicines manufacturers: 16
• Medicines expenditure growth 17% per annum compared to GDP growth of 3.3%
10/04/23MeTA 2
10/04/23MeTA 3
What is MeTA?
MeTA brings together at the international and national levels, a diverse group of people working in the pharmaceutical sector through a (multi-stakeholders approach) to find ways to improve/increase transparency and accountability in selection, regulation, procurement, distribution and use of medicines in countries
MeTA partners are the UK Department for International Development (DFID) , the WHO and the World Bank (WB)
10/04/23MeTA 4
Agenda
A. MeTA Process in Jordan
B. MeTA Progress in Jordan ( achievements so far)
C. Monitoring and Evaluation
D. Challenges
E. Key Successes
F. Getting more information
MeTA Process in Jordan:
1. It started with scoping visits
2. Looked into reasons for Jordan to be one of the MeTA pilot Countries
3. Proposal was sent to the Government
4. The Government approved
5. Formed the MeTA Council / stakeholder
6. Drafting Jordan’s Workplan
7. MOU signed
10/04/23MeTA 5
10/04/23MeTA 6
MeTA in Jordan
MeTA Process in Jordan:
The Minister of Health sent an official letter to MOPIC approving on having the High Health Council (HHC) hosting the MeTA Secretariat
10/04/23MeTA 7
MeTA Process in Jordan:
Jordan’s MeTA Council held its first meeting at the HHC in August 2008 after the MeTA council was formed and endorsed by the MOH, the council representation is from the Government, private sector, civil society organizations, professional organizations, and the academia. In addition non- voting representatives from the World Bank (WB), the World Health Organization (WHO) and Health Action international (HAI), with the presence of the MeTA national consultant in Jordan
10/04/23MeTA 8
MeTA Process in Jordan:
The Council serves as the highest policy making and consultative body
The council elected his chairperson Dr Taher AbuElSamen and also nominated him to participate as Jordan’s representative on the MeTA International Advisory Group (MIAG) in London every year
10/04/23MeTA 9
MeTA Process in Jordan:
The MeTA Council drafted the internal rules and formed Three Committees then developed activities for the areas of work that they chose and included them in the Jordan MeTA workplan
Jordan MeTA workplan has been sent officially to the MMB on the 9th of February 2009 for approval, and it was approved after 7 working days, MOU was signed accordingly
10/04/23MeTA 10
MeTA Process in Jordan:
The three committees that have been formed out of the MeTA Council are:
1- Evidence Based Decision Making for the RDL Committee
2- Encouraging Best Practice and Promote Rational Drug Use Committee
3- Civil Society organizations Building Capacity Committee
10/04/23MeTA 11
MeTA Progress in Jordan
Supply Chain Mapping Private Sector Mapping CSO Mapping NICE Training on Using Health Technology
Assessment to inform decision-making in healthcare
MeTA Chair has Participated in the MIAG meeting Held an important session on medicines and
transparency at the WHA
10/04/23MeTA 12
WHA 62 Geneva 2009
MeTA Jordan held an important session on medicines and transparency and Good Governance at the WHA, Geneva, on19th May. Over 80 participants from the WHA attended with representatives from over 20 different countries including Iraq, Libia,Ghana, Cameroon, Peru, Argentina, India, and Bangladesh
Members of the MeTA Jordan Council presented the work they have done so far in setting up a multi-stakeholder group comprising representatives from Government, the pharmaceutical industry, and civil society organizations
10/04/23MeTA 13
Monitoring and Evaluation
Monthly progress reports of three working committees and MeTA Jordan Secretariat
Quarterly reports by MeTA Council to International MeTA Secretariat Reports will be published on national & international MeTA websites
Financial reporting by national MeTA Secretariat
External monitor from another MeTA pilot country on annual and also the CSO Alliance could be involved in the monitoring and evaluation process
10/04/23MeTA 14
Challenges
Assuring commitment & engagement of ALL stakeholders
Clarity and understanding of MeTA’s objectives to Jordan’s MeTA Council stakeholders at ALL levels of their organisations
Lack of good quality information and data
Civil Society are in early stages of development How to make the MeTA approach SUSTAINABLE The concept behind MeTA processes to be country-led, that
in a way caused the process in Jordan to be slower
10/04/23MeTA 15
Key Successes
The full support from the Jordanian government, MOH and MOPIC
The full support from the international MeTA Secretariat
WHO Jordan Country Representative was very supportive
10/04/23MeTA 16
Key Successes
DFID, WHO/HQ, WB and WHO/EMRO regional office were very supportive
Cooperation between all stakeholders including the private sector and the Council members from all sectors were highly committed to moving the MeTA process forward
10/04/23MeTA 17
10/04/23MeTA 18
References for getting more Information:
http://www.medicinestransparency.org/meta-countries/jordan/ http://www.haiweb.org/medicineprices/surveys/200405JO/survey_report.pdf http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHA-Briefing-
note.pdf http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHA-MeTA-Country-
Jordan.pdf http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHO-HAI-summary-
report.pdf http://www.medicinestransparency.org/news-events/article/view/information-about-
medicines-where-to-start/80/
10/04/23MeTA 19
Thank you!
Rania Bader Email: [email protected] Mobile number +962 79 5691921
MeTA: www.MedicinesTransparency.org